Contribution of chromosome 9p21-22 deletion to the progression of human renal cell carcinoma.
To investigate the possible role of genomic aberrations of chromosome 9p21-22 in the tumorigenesis of human renal cell carcinoma (RCC), 10 RCC cell lines, 55 primary RCCs and 5 metastatic lesions were studied by Southern blotting and polymerase chain reaction-based analysis. Nine of 10 RCC cell lines showed a homozygous deletion of MTSI/CDKN2/(p16), while only 1 in 55 primary tumors had this deletion. Loss of heterozygosity on 9p21-22 was observed in 5 of 10 informative primary RCCs from patients with metastasis, but in only 4 of 31 informative tumors (13%) without metastasis (P = 0.025). Futhermore, 3 of 5 metastatic tumors (60%) showed hemi- or homozygous deletion of MTSI/CDKN2. These results indicate that the 9p21-22 deletion may be a relatively late event in RCC tumorigenesis and could be associated with RCC metastasis.
Kinoshita
H
H
Department of Urology, Faculty of Medicine, Kyoto University.
Yamada
H
H
Ogawa
O
O
Kakehi
Y
Y
Osaka
M
M
Nakamura
E
E
Mishina
M
M
Habuchi
T
T
Takahashi
R
R
Sugiyama
T
T
D000483:Alleles; D002292:Carcinoma, Renal Cell / Q000235:genetics*; D002352:Carrier Proteins / Q000235:genetics; D002872:Chromosome Deletion; D002899:Chromosomes, Human, Pair 9; D019941:Cyclin-Dependent Kinase Inhibitor p16; D018450:Disease Progression; D016147:Genes, Tumor Suppressor; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics*; D016133:Polymerase Chain Reaction; D014407:Tumor Cells, Cultured
D002352:Carrier Proteins; D019941:Cyclin-Dependent Kinase Inhibitor p16